Search

Displaying results 2471 - 2480 of 9313 in total
  1. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).

  2. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. … It was rejected for approval for use in the United States.

  3. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    Sensitivity to ethylenediamine may be identified with a clinical patch test. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.

  4. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. … Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure.

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Aripiprazole

    go.drugbank.com/drugs/DB01238
    ApprovedInvestigational

    Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Topotecan

    go.drugbank.com/drugs/DB01030
    ApprovedInvestigational

    An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

  7. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115]. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  8. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. … [L64039,L64040] It is the first targeted cancer medicine approved from the class of RAS(ON) multi-selective and mutant-selective inhibitors.[L64041]

  9. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    [A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib]. … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal

  10. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones. … The pharmacological actions of alfacalcidol are prolonged than vitamin D because a negative feedback mechanism regulates the final activation step of vitamin D in the kidneys.

    Synonyms: (5Z,7E)-9,10-seco-5,7,10(19)-cholestatrien-1α,3β-diol